Mutations in two blood pressure-related genes — angiotensinogen (AGT) and angiotensin-converting enzyme (ACE) — may increase a person’s risk of being overweight or obese, according to a study of Tunisians. While previous studies in several ethnic populations have reported conflicting results, these findings support the existence of a…
The U.S. Food and Drug Administration (FDA) has accepted and given priority review to Rhythm Pharmaceuticals’ request that setmelanotide be approved to treat people with POMC deficiency and LEPR deficiency, two rare genetic obesity disorders. This priority status is expected to shorten setmelanotide’s regulatory review to…
Rhythm Pharmaceuticals is seeking approval from the U.S. Food and Drug Administration (FDA) for its lead candidate setmelanotide to treat POMC deficiency and LEPR deficiency, two rare genetic obesity disorders. Over the next two months, the FDA will determine whether Rhythm’s new drug application (NDA) is acceptable for filing…
The offspring of obese mothers are more likely to age faster, and to develop metabolic diseases such as diabetes and heart disease, a study in rats shows. While the health problems spanned the offsprings’ lifetimes, the researchers noted that “encouragingly, exercise by the offspring improves many of the poor offspring…
Get regular updates delivered to your inbox.